Among Japanese patients with tumor PD-L1 expression level of 1% or more (nivolumab, n = 11; placebo, n = 8), the median NUTRFS was 32.95 months (95% CI 2.63–NR) in the nivolumab group and not reached (95% CI 5.59−NR) in the placebo group. The gene discussed is CD274; the disease is neoplasm.